John F. Paolini - Jul 25, 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Jul 25, 2023
Transactions value $
-$501,220
Form type
4
Date filed
7/27/2023, 04:30 PM
Previous filing
Apr 11, 2023
Next filing
Sep 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise $53.9K +29K +69.2% $1.86* 70.9K Jul 25, 2023 Direct F1
transaction KNSA Class A Common Share Sale -$93.7K -5.2K -7.33% $18.01 65.7K Jul 25, 2023 Direct F1, F2
transaction KNSA Class A Common Share Sale -$311K -16.2K -24.61% $19.25 49.5K Jul 25, 2023 Direct F1, F3
transaction KNSA Class A Common Share Sale -$150K -7.63K -15.41% $19.69 41.9K Jul 25, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -29K -17.14% $0.00 140K Jul 25, 2023 Class A Common Share 29K $1.86 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.50 to $18.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.50 to $19.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.50 to $19.94. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F5 The option is fully vested and exercisable.